Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DNA polymerase III PolC-type (*PolC*) is a major replicative DNA polymerase operating in Gram-positive bacteria, responsible for synthesizing the bulk of DNA during cell division[3][8]. PolC possesses both polymerase and 3' to 5' exonuclease (proofreading) activity, ensuring high fidelity of replication[3][8]. Structurally, PolC displays a right-hand configuration, with distinct thumb, palm, and finger domains for DNA binding and catalysis. It also contains an oligonucleotide/oligosaccharide-binding (OB) domain and a polymerase and histidinol phosphatase (PHP) domain[3]. Recent structural models have revealed specialized mechanisms for error sensing and proofreading, highlighting PolC as a compelling target for new antibiotics, given its essential role in bacterial viability and absence from mammalian genomes[3][1][8].
Drugs inhibiting PolC act by blocking DNA replication, thereby stopping bacterial cell division and proliferation
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DNA polymerase III PolC-type (PolC).